

GLAXOSMITHKLINE PLC

Form 6-K

February 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards and Shares withheld or sold to meet tax liabilities

This notification sets out the details of the vesting of awards and the sale or withholding of shares to meet tax liabilities over Ordinary Shares made in 2016 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group. The restricted period for the 2016 SVP awards has now ended and the awards made to Persons Discharging Managerial Responsibility (PDMRs) vested on 11 February 2019.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr J Ford
 - b) Position / status SVP & General Counsel
 - c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
 - b) Nature of the transaction The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
n/a	6,320

 Aggregated information n/a (single transaction)
 - d) Aggregated volume
Price
 - e) Date of the transaction 2019-02-11
 - f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr J Ford
 - b) Position / status SVP & General Counsel
 - c) Initial notification / amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	American Depositary Shares ('ADSs')
a) Description of the financial instrument	ISIN: US37733W1053
b) Nature of the transaction	The sale of ADSs to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) \$40.2654 3,113
Aggregated information	n/a (single transaction)
d) Aggregated volume	
Price	
e) Date of the transaction	2019-02-11
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr B McNamara
b) Position / status	CEO, GSK Consumer Healthcare
c) Initial notification / amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	American Depositary Shares ('ADSs')
a) Description of the financial instrument	ISIN: US37733W1053
b) Nature of the transaction	The vesting and release of ADSs awarded in 2016 under the Company's 2009 Share Value Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) n/a 11,212
d) Aggregated information	n/a (single transaction)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume
Price

e) Date of the transaction 2019-02-11

f) Place of the transaction New York Stock Exchange
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara

b) Position / status CEO, GSK Consumer
Healthcare

c) Initial notification / amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

American Depositary Shares
(‘ADSs’)

a) Description of the financial instrument
ISIN: US37733W1053

b) Nature of the transaction
The sale of ADSs to meet tax
liabilities further to the
vesting and release of the
2016 award under the
Company's 2009 Share Value
Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
\$40.2654	5,522
Aggregated information n/a (single transaction)	

d) Aggregated volume
Price

e) Date of the transaction 2019-02-11

f) Place of the transaction New York Stock Exchange
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R Simard

b) Position/status President, Pharma Supply
Chain

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	n/a	11,060
Aggregated information	n/a (single transaction)	
d) Aggregated volume		
e) Date of the transaction	2019-02-11	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr R Simard
b) Position/status	President, Pharma Supply Chain
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5380	5,199
d) Aggregated information	n/a (single transaction)	

Aggregated volume

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Price

- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction The vesting and release of Ordinary Shares awarded in 2016 under the Company's 2009 Share Value Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
n/a	11,060
Aggregated information	
n/a (single transaction)	

- d) Aggregated volume
Price

- e) Date of the transaction 2019-02-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities further to the vesting and release of the 2016 award under the Company's 2009 Share Value Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.5380	5,199
Aggregated information	n/a (single transaction)	
d) Aggregated volume		
Price		
e) Date of the transaction	2019-02-11	
f) Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 12, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc